Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persephone: 6 vs 12 months trastuzumab in early HER2-positive breast cancer
2006-007018-39Phase 3Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of trastuzumab in breast cancer (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Disease-free survival and Overall survival. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-007018-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007018-39.